BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
复制标题
DOI：
10.1177/0269881112444324
复制
发表时间：
2012-07-01
影响因子：
4.1
通讯作者：
Winstock, A.
中科院分区：
文献类型：
--
作者：
Lingford-Hughes, A. R.;Welch, S.;Winstock, A.
英国精神药理学协会关于药物滥用、有害使用、成瘾和精神障碍合并症的治疗准则主要侧重于药物管理。它们明确地基于现有证据，并作为建议提出，以帮助从业者进行临床决策，同时对证据进行详细审查。一个由治疗这些疾病的专家参加的共识会议审查了关键领域，并考虑了证据的强度和临床意义。这些准则是根据与会者的反馈意见拟订的。这些准则主要涉及药物戒断、短期和长期替代、维持禁欲和预防并发症的药理学管理，酌情涉及药物滥用或有害使用或成瘾以及怀孕、合并精神障碍和年轻人和老年人的管理。
The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people.